<?xml version='1.0' encoding='utf-8'?>
<document id="31119689"><sentence text="Pharmacokinetic Drug Interactions Between Amlodipine, Valsartan, and Rosuvastatin in Healthy Volunteers."><entity charOffset="42-52" id="DDI-PubMed.31119689.s1.e0" text="Amlodipine" /><entity charOffset="54-63" id="DDI-PubMed.31119689.s1.e1" text="Valsartan" /><entity charOffset="69-81" id="DDI-PubMed.31119689.s1.e2" text="Rosuvastatin" /><pair ddi="false" e1="DDI-PubMed.31119689.s1.e0" e2="DDI-PubMed.31119689.s1.e0" /><pair ddi="false" e1="DDI-PubMed.31119689.s1.e0" e2="DDI-PubMed.31119689.s1.e1" /><pair ddi="false" e1="DDI-PubMed.31119689.s1.e0" e2="DDI-PubMed.31119689.s1.e2" /><pair ddi="false" e1="DDI-PubMed.31119689.s1.e1" e2="DDI-PubMed.31119689.s1.e1" /><pair ddi="false" e1="DDI-PubMed.31119689.s1.e1" e2="DDI-PubMed.31119689.s1.e2" /></sentence><sentence text="Amlodipine, valsartan, and rosuvastatin are among the medications widely coadministered for the treatment of hyperlipidemia accompanied by hypertension"><entity charOffset="0-10" id="DDI-PubMed.31119689.s2.e0" text="Amlodipine" /><entity charOffset="12-21" id="DDI-PubMed.31119689.s2.e1" text="valsartan" /><entity charOffset="27-39" id="DDI-PubMed.31119689.s2.e2" text="rosuvastatin" /><pair ddi="false" e1="DDI-PubMed.31119689.s2.e0" e2="DDI-PubMed.31119689.s2.e0" /><pair ddi="false" e1="DDI-PubMed.31119689.s2.e0" e2="DDI-PubMed.31119689.s2.e1" /><pair ddi="false" e1="DDI-PubMed.31119689.s2.e0" e2="DDI-PubMed.31119689.s2.e2" /><pair ddi="false" e1="DDI-PubMed.31119689.s2.e1" e2="DDI-PubMed.31119689.s2.e1" /><pair ddi="false" e1="DDI-PubMed.31119689.s2.e1" e2="DDI-PubMed.31119689.s2.e2" /></sentence><sentence text=" The aim of this study was to investigate the possible pharmacokinetic drug-drug interactions between amlodipine, valsartan, and rosuvastatin in healthy Korean male volunteers"><entity charOffset="102-112" id="DDI-PubMed.31119689.s3.e0" text="amlodipine" /><entity charOffset="114-123" id="DDI-PubMed.31119689.s3.e1" text="valsartan" /><entity charOffset="129-141" id="DDI-PubMed.31119689.s3.e2" text="rosuvastatin" /><pair ddi="false" e1="DDI-PubMed.31119689.s3.e0" e2="DDI-PubMed.31119689.s3.e0" /><pair ddi="false" e1="DDI-PubMed.31119689.s3.e0" e2="DDI-PubMed.31119689.s3.e1" /><pair ddi="false" e1="DDI-PubMed.31119689.s3.e0" e2="DDI-PubMed.31119689.s3.e2" /><pair ddi="false" e1="DDI-PubMed.31119689.s3.e1" e2="DDI-PubMed.31119689.s3.e1" /><pair ddi="false" e1="DDI-PubMed.31119689.s3.e1" e2="DDI-PubMed.31119689.s3.e2" /></sentence><sentence text="" /><sentence text="In this phase 1, open-label, multiple-dose, two-part, two-period, fixed-sequence study, the enrolled subjects were randomized into two parts (A and B)" /><sentence text=" In part A (n = 32), each subject received one fixed-dose combination (FDC) tablet of amlodipine/valsartan 10 mg/160 mg alone for 10 consecutive days in period I, and the same FDC for 10 days with concomitant 7-day administration of 20 mg rosuvastatin in period II"><entity charOffset="86-96" id="DDI-PubMed.31119689.s6.e0" text="amlodipine" /><entity charOffset="97-106" id="DDI-PubMed.31119689.s6.e1" text="valsartan" /><entity charOffset="239-251" id="DDI-PubMed.31119689.s6.e2" text="rosuvastatin" /><pair ddi="false" e1="DDI-PubMed.31119689.s6.e0" e2="DDI-PubMed.31119689.s6.e0" /><pair ddi="false" e1="DDI-PubMed.31119689.s6.e0" e2="DDI-PubMed.31119689.s6.e1" /><pair ddi="false" e1="DDI-PubMed.31119689.s6.e0" e2="DDI-PubMed.31119689.s6.e2" /><pair ddi="false" e1="DDI-PubMed.31119689.s6.e1" e2="DDI-PubMed.31119689.s6.e1" /><pair ddi="false" e1="DDI-PubMed.31119689.s6.e1" e2="DDI-PubMed.31119689.s6.e2" /></sentence><sentence text=" In part B (n = 25), each subject received rosuvastatin alone for 7 days in period I, and the FDC for 10 days with concomitant 7-day administration of rosuvastatin in period II"><entity charOffset="43-55" id="DDI-PubMed.31119689.s7.e0" text="rosuvastatin" /><entity charOffset="151-163" id="DDI-PubMed.31119689.s7.e1" text="rosuvastatin" /><pair ddi="false" e1="DDI-PubMed.31119689.s7.e0" e2="DDI-PubMed.31119689.s7.e0" /><pair ddi="false" e1="DDI-PubMed.31119689.s7.e0" e2="DDI-PubMed.31119689.s7.e1" /></sentence><sentence text=" In both parts, there was a 12-day washout between periods" /><sentence text=" Serial blood samples were collected for up to 72 h for amlodipine and rosuvastatin, and for up to 48 h for valsartan after the last dose of each period"><entity charOffset="56-66" id="DDI-PubMed.31119689.s9.e0" text="amlodipine" /><entity charOffset="71-83" id="DDI-PubMed.31119689.s9.e1" text="rosuvastatin" /><entity charOffset="108-117" id="DDI-PubMed.31119689.s9.e2" text="valsartan" /><pair ddi="false" e1="DDI-PubMed.31119689.s9.e0" e2="DDI-PubMed.31119689.s9.e0" /><pair ddi="false" e1="DDI-PubMed.31119689.s9.e0" e2="DDI-PubMed.31119689.s9.e1" /><pair ddi="false" e1="DDI-PubMed.31119689.s9.e0" e2="DDI-PubMed.31119689.s9.e2" /><pair ddi="false" e1="DDI-PubMed.31119689.s9.e1" e2="DDI-PubMed.31119689.s9.e1" /><pair ddi="false" e1="DDI-PubMed.31119689.s9.e1" e2="DDI-PubMed.31119689.s9.e2" /></sentence><sentence text=" The plasma concentrations of amlodipine, valsartan, and rosuvastatin were determined by using liquid chromatography-tandem mass spectrometry"><entity charOffset="30-40" id="DDI-PubMed.31119689.s10.e0" text="amlodipine" /><entity charOffset="42-51" id="DDI-PubMed.31119689.s10.e1" text="valsartan" /><entity charOffset="57-69" id="DDI-PubMed.31119689.s10.e2" text="rosuvastatin" /><pair ddi="false" e1="DDI-PubMed.31119689.s10.e0" e2="DDI-PubMed.31119689.s10.e0" /><pair ddi="false" e1="DDI-PubMed.31119689.s10.e0" e2="DDI-PubMed.31119689.s10.e1" /><pair ddi="false" e1="DDI-PubMed.31119689.s10.e0" e2="DDI-PubMed.31119689.s10.e2" /><pair ddi="false" e1="DDI-PubMed.31119689.s10.e1" e2="DDI-PubMed.31119689.s10.e1" /><pair ddi="false" e1="DDI-PubMed.31119689.s10.e1" e2="DDI-PubMed.31119689.s10.e2" /></sentence><sentence text="" /><sentence text="Fifty-seven subjects were enrolled; 30 and 25 subjects completed part A and part B, respectively" /><sentence text=" The geometric mean ratios and 90% confidence intervals for the maximum plasma concentration at steady state (Cmax,ss) and the area under the plasma concentration-time curve over the dosing interval at steady state (AUCτ,ss) were 0" /><sentence text="9389 (0" /><sentence text="9029-0" /><sentence text="9763) and 0" /><sentence text="9316 (0" /><sentence text="8970-0" /><sentence text="9675) for amlodipine, 0"><entity charOffset="10-20" id="DDI-PubMed.31119689.s19.e0" text="amlodipine" /></sentence><sentence text="7698 (0" /><sentence text="6503-0" /><sentence text="9114) and 0" /><sentence text="7888 (0" /><sentence text="6943-0" /><sentence text="8962) for valsartan, and 0"><entity charOffset="10-19" id="DDI-PubMed.31119689.s25.e0" text="valsartan" /></sentence><sentence text="9737 (0" /><sentence text="8312-1" /><sentence text="1407) and 0" /><sentence text="9596 (0" /><sentence text="8826-1" /><sentence text="0433) for rosuvastatin, respectively"><entity charOffset="10-22" id="DDI-PubMed.31119689.s31.e0" text="rosuvastatin" /></sentence><sentence text=" Of the 57 subjects enrolled in this study, 10 subjects experienced 13 adverse events (AEs); no severe or serious AEs were reported" /><sentence text="" /><sentence text="When amlodipine, valsartan, and rosuvastatin were coadministered to healthy volunteers, the pharmacokinetic exposure to valsartan was decreased, but no change in exposure to amlodipine and rosuvastatin occurred"><entity charOffset="5-15" id="DDI-PubMed.31119689.s34.e0" text="amlodipine" /><entity charOffset="17-26" id="DDI-PubMed.31119689.s34.e1" text="valsartan" /><entity charOffset="32-44" id="DDI-PubMed.31119689.s34.e2" text="rosuvastatin" /><entity charOffset="120-129" id="DDI-PubMed.31119689.s34.e3" text="valsartan" /><entity charOffset="174-184" id="DDI-PubMed.31119689.s34.e4" text="amlodipine" /><entity charOffset="189-201" id="DDI-PubMed.31119689.s34.e5" text="rosuvastatin" /><pair ddi="false" e1="DDI-PubMed.31119689.s34.e0" e2="DDI-PubMed.31119689.s34.e0" /><pair ddi="false" e1="DDI-PubMed.31119689.s34.e0" e2="DDI-PubMed.31119689.s34.e1" /><pair ddi="false" e1="DDI-PubMed.31119689.s34.e0" e2="DDI-PubMed.31119689.s34.e2" /><pair ddi="false" e1="DDI-PubMed.31119689.s34.e0" e2="DDI-PubMed.31119689.s34.e3" /><pair ddi="false" e1="DDI-PubMed.31119689.s34.e0" e2="DDI-PubMed.31119689.s34.e4" /><pair ddi="false" e1="DDI-PubMed.31119689.s34.e0" e2="DDI-PubMed.31119689.s34.e5" /><pair ddi="false" e1="DDI-PubMed.31119689.s34.e1" e2="DDI-PubMed.31119689.s34.e1" /><pair ddi="false" e1="DDI-PubMed.31119689.s34.e1" e2="DDI-PubMed.31119689.s34.e2" /><pair ddi="false" e1="DDI-PubMed.31119689.s34.e1" e2="DDI-PubMed.31119689.s34.e3" /><pair ddi="false" e1="DDI-PubMed.31119689.s34.e1" e2="DDI-PubMed.31119689.s34.e4" /><pair ddi="false" e1="DDI-PubMed.31119689.s34.e1" e2="DDI-PubMed.31119689.s34.e5" /><pair ddi="false" e1="DDI-PubMed.31119689.s34.e2" e2="DDI-PubMed.31119689.s34.e2" /><pair ddi="false" e1="DDI-PubMed.31119689.s34.e2" e2="DDI-PubMed.31119689.s34.e3" /><pair ddi="false" e1="DDI-PubMed.31119689.s34.e2" e2="DDI-PubMed.31119689.s34.e4" /><pair ddi="false" e1="DDI-PubMed.31119689.s34.e2" e2="DDI-PubMed.31119689.s34.e5" /><pair ddi="false" e1="DDI-PubMed.31119689.s34.e3" e2="DDI-PubMed.31119689.s34.e3" /><pair ddi="false" e1="DDI-PubMed.31119689.s34.e3" e2="DDI-PubMed.31119689.s34.e4" /><pair ddi="false" e1="DDI-PubMed.31119689.s34.e3" e2="DDI-PubMed.31119689.s34.e5" /><pair ddi="false" e1="DDI-PubMed.31119689.s34.e4" e2="DDI-PubMed.31119689.s34.e4" /><pair ddi="false" e1="DDI-PubMed.31119689.s34.e4" e2="DDI-PubMed.31119689.s34.e5" /></sentence><sentence text=" All treatments were well tolerated" /><sentence text="" /><sentence text="https://cris" /><sentence text="nih" /><sentence text="go" /><sentence text="kr CRIS KCT0001660" /><sentence text="" /><sentence text="KyungDong Pharmaceutical Corp" /><sentence text=" Ltd" /><sentence text=", Seoul, Republic of Korea" /><sentence text="" /></document>